VIR — Vir Biotechnology, Inc.

Summary of Vir Biotechnology, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Cash Position: As of March 31, 2026, Vir had approximately $809.3 million in cash, cash equivalents, and investments. This figure does not include $315 million from the recently closed Astellas collaboration.
• Net Loss: The company reported a net loss of $125.7 million for Q1 2026, compared to a net loss of $121.0 million in Q1 2025.
• R&D Expenses: R&D expenses were $108.9 million, down from $118.6 million year-over-year, primarily due to a one-time payment to Alnylam in 2025.
• SG&A Expenses: SG&A expenses were slightly reduced to $23.3 million from $23.9 million in the previous year.

2. Strategic Updates and Business Highlights:

• Collaboration with Astellas: The partnership, valued at up to $1.7 billion, aims to co-develop VIR-5500, a prostate cancer treatment. Astellas will handle 60% of global development costs, and both companies will share U.S. commercial profits equally.
• Clinical Advancements:
  • VIR-5500: Positive Phase 1 data showed a favorable safety profile and promising efficacy in heavily pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC). The company plans to initiate a Phase 3 program in 2027.
  • Hepatitis Delta Program: The combination therapy of tobevibart and elebsiran demonstrated significant efficacy, with 88% of evaluable participants achieving undetectable virus at Week 96. The regimen is positioned as a best-in-class option with monthly dosing.

3. Forward Guidance and Outlook:

• Vir expects its cash runway to extend into 2028, allowing for continued investment in its clinical pipeline.
• The company anticipates reporting topline data from the ECLIPSE 1 trial for hepatitis delta in Q4 2026, with further data from ECLIPSE 2 and 3 expected in Q1 2027.
• The company is focused on disciplined capital allocation to maximize long-term value while advancing multiple clinical studies.

4. Bad News, Challenges, or Points of Concern:

• Net Loss: The increase in net loss year-over-year raises concerns about financial sustainability, especially in the face of ongoing high R&D expenditures.
• Competitive Landscape: The company faces competition in both the hepatitis delta and oncology markets, with emerging therapies from competitors that could impact market share.
• Regulatory Risks: While the company has received Breakthrough Therapy and Fast Track designations, the success of upcoming trials is critical for regulatory approvals and market entry.

5. Notable Q&A Insights:

• HER2 Development: There is cautious interest in expanding the HER2-targeted T cell engager (VIR-5818) into breast cancer, pending data from ongoing trials.
• Durability Metrics: For VIR-5500, the company will evaluate a combination of PSA, RECIST, and rPFS data to determine the viability of moving into Phase 3 trials.
• Pricing Strategy for HDV: The company is considering a pricing strategy for hepatitis delta therapy that aligns with existing treatments, estimating a price range of $150,000 to $250,000.
• ECLIPSE Trial Requirements: A combination of data from ECLIPSE 1 and ECLIPSE 2 will be necessary for a BLA filing, with ECLIPSE 1 data expected to provide a favorable comparison against existing therapies.

Overall, Vir Biotechnology is making significant strides in its clinical programs while navigating financial challenges and competitive pressures. The upcoming data readouts and strategic collaborations are crucial for the company's future growth and market positioning.